Distance to treatment as a factor for loss to follow up of hepatitis C patients in North East England

Simpson, Hamish; Manley, Petra; Lawler, J.; Morey, Sarah; Buchanan, Emma; Hewett, M; Knowles, Joshua; Miller, Carolyn; McCarron, Brendan; Valappil, Manoj; McPherson, Stuart

doi:10.1093/pubmed/fdy190

Cited by 15 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient’s residence also influenced his decision on returning to the hospitals for further evaluation [ 22 ]. One study in England revealed that the treated HCV patients lived closer to the hospitals than the patients lost to follow-up did and living within 4 km of a treatment hospital was a strong indicator of having started treatment [ 23 ]. In line with that study, our study showed that the patients living in Taoyaun City were more willing to return to our hospital than the patients in Northern Taiwan (except Taoyuan City) and other cities in Taiwan.…”

Section: Discussionmentioning

confidence: 99%

“…The patient's residence also influenced his decision on returning to the hospitals for further evaluation [22]. One study in England revealed that the treated HCV patients lived closer to the hospitals than the patients lost to follow-up did and living within 4 km of a treatment hospital was a strong indicator of having started treatment [23].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C micro-elimination through the retrieval strategy of patients lost to follow-up

Chen

Huang²,

Hsu³

et al. 2023

BMC Gastroenterol

View full text Add to dashboard Cite

Background and aim World Health Organization sets up an ambitious and attainable goal to eliminate hepatitis C (HCV) by 2030. The previous diagnosed HCV patients lost to follow-up were considered as an important target group for HCV elimination. We conducted a call back program to retrieve the lost to follow-up HCV patients and link them to care in our hospital. By analyzing and comparing our result with that from other studies, we wish to improve our retrieval strategy and provide our experience to the general communities. Methods A list of the patients with a medical record showing seropositive for antibody to HCV (anti-HCV Ab) from 2004 to 2017 was retrieved by the department of intelligent technology of our hospital. Three dedicated staff members reviewed the patients’ electronic medical records (EMRs) and recruited the patient lost follow-up to the call back program. The staff members contacted the qualified patients by telephone and inquired about their opinions for treating their chronic HCV infection. We also informed the patients about the retrieval strategy and why we contact them. As our National Health Insurance request, we gave all patient one informed consent for hepatitis C treatment. Informed consents have been obtained from all patients. Referrals to our gastroenterology unit (GU) were arranged for the patients who would like to continue their chronic HCV care in our hospital. Results There were 31,275 anti-HCV positive patients. We included 11,934 patients (38.2%) into the call back system and contacted them by telephone. Based on the response to our call, we ascertained 1277 eligible cases (10.7%) for retrieval. The patients who were younger (< 55), lived in Taoyaun City or had tested positive for anti-HCV Ab at the department of internal medicine department had an increased rate of successful call back. There were 563 patients (44.1%) returning to our GU. Of them, 354 patients (62.9%) were positive for HCV viremia. 323 patients (91.2%) received the DAAs treatment. The SVR12 with Grazoprevir + elbasvir, Glecaprevir + pibrentasvir, Sofosbuvir + ledipasvir and Sofosbuvir + velpatasvir were 97.9%, 98.8%, 100% and 97.5%, respectively. Conclusions Call back system can expand our reach to those unaware or ignoring chronic HCV infection patients and link them to treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Hepatitis C micro-elimination through the retrieval strategy of patients lost to follow-up

Chen

Huang²,

Hsu³

et al. 2023

BMC Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Moving care delivery out of hospital settings may improve attrition rates. One study from the North-East of England found that distance from a HCV treatment service was a major predictor of patients not commencing antivirals[ 84 ]. DAAs can be effectively delivered in non-hospital settings, increasing access to treatment.…”

Section: Hepatitis C Virusmentioning

confidence: 99%

Viral hepatitis in 2021: The challenges remaining and how we should tackle them

Dunn¹,

Wetten²,

McPherson³

et al. 2022

WJG

View full text Add to dashboard Cite

Viral hepatitis results in 1.4 million deaths annually. The World Health Organization (WHO) set an ambitious target to eliminate viral hepatitis by 2030, but significant challenges remain. These include inequalities in access to healthcare, reaching at risk populations and providing access to screening and effective treatment. Stigma around viral hepatitis persists and must be addressed. The WHO goal of global elimination by 2030 is a worthy aim, but remains ambitious and the coronavirus 2019 pandemic undoubtedly has set back progress. This review article will focus on hepatitis A to E, highlighting problems that have been resolved in the field over the past decade, those that remain to be resolved and suggest directions for future problem solving and research.

show abstract

“…This individual follow-up intention might have great effects on patient adherence, regardless of social security, the medical environment and other essential indexes. Moreover, adherence may be affected by personal economic status, education level of patients and the how important the patients believe the disease is, as well as the convenience of medical sites [87]. For patients with poor adherence, the harm increases in terms of tumour progression or recurrence, potentially resulting in lifethreatening effects.…”

Section: Adherence and Cultural Environmentmentioning

confidence: 99%

Continuing controversy regarding individualized surgical decision-making for patients with 1–4 cm low-risk differentiated thyroid carcinoma: A systematic review

Liu

Yan²,

Cheng

2020

European Journal of Surgical Oncology

View full text Add to dashboard Cite

Implementing high-quality randomized controlled trials is difficult for patients with 1e4 cm low-risk differentiated thyroid carcinoma (DTC). Controversy exists regarding whether lobectomy (LT) or total thyroidectomy (TT) is the optimal surgical approach over the short term and long term. Inconsistent recommendations have led to confusion amongst surgeons. Consequently, the outcomes of patients may be influenced. A great deal of new literature is published monthly, and there have been numerous studies supporting both LT and TT. Surgeons must spend considerable time and energy clarifying why controversy exists and which studies should be used as references. We selected 19 recent guidelines/consensuses for surgical approach in treating of 1e4 cm DTC. This study presents various topics relevant to the present debate, including disease-specific survival (DSS), persistence/recurrence, and complications between LT and TT, in patients with 1e4 cm low-risk DTC. This review includes a discussion of the background of those recommendations with regard to various medical, cultural and geographic environments. Additionally, recent technologies and future directions for current issues in risk identification were integrated into the review to provide a reference for individualized decision-making for patients with 1e4 cm low-risk DTC. Given different national conditions, there are different points of emphasis amongst the guidelines. Consideration of surgical approach should consider the character of both surgeons and patients. We should balance the relative benefits, risks and resulting quality of life in order to perform individualized surgical decision-making, and to make reasonable decisions in employing either TT or LT.

show abstract

Distance to treatment as a factor for loss to follow up of hepatitis C patients in North East England

Cited by 15 publications

References 14 publications

Hepatitis C micro-elimination through the retrieval strategy of patients lost to follow-up

Hepatitis C micro-elimination through the retrieval strategy of patients lost to follow-up

Viral hepatitis in 2021: The challenges remaining and how we should tackle them

Continuing controversy regarding individualized surgical decision-making for patients with 1–4 cm low-risk differentiated thyroid carcinoma: A systematic review

Contact Info

Product

Resources

About